NEW YORK (GenomeWeb) – Roche today announced the final results of its tender offer to purchase up to 15.6 million shares of common stock of Foundation Medicine at $50 per share, after disclosing preliminary results last week.

Foundation Medicine shareholders tendered a total of nearly 18.8 million shares of common stock. Because the offer was oversubscribed, Roche will accept 83.2 percent of shares offered by each tendering stockholder for purchase.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.